Protagenic Therapeutics Announces Timeline for Form 10-Q Filing and Nasdaq Compliance Update
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 22 2025
0mins
Should l Buy ?
Source: SeekingAlpha
Quarterly Report Filing Delay: Protagenic Therapeutics announced a delay in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2025, due to merger-related financial statement consolidation.
Anticipated Brief Delay: The company expects the delay to be short, but cannot guarantee a specific timeline for the filing.
Nasdaq Notice Received: Protagenic confirmed it received a notice from Nasdaq regarding its failure to file the Quarterly Report, although this does not affect the trading of its securities.
Current Stock Performance: Following the announcement, Protagenic's stock price increased by 1.41% after hours, reaching $4.3.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
